Verzistobart

DB18895InvestigationalProtein Based Therapies

Verzistobart is under investigation in clinical trial NCT06056895 (Triple Immune Checkpoint Inhibition for Advanced or Metastatic PD-(L)1 Refractory Merkel Cell Carcinoma).

Mechanism: Pharmacologically active on Hepatitis A virus cellular receptor 2
Curator reviewed
Also known as: INCAGN 02390

Resolves to

Compound

UNIIKAC8QY6TMNCAS2649466-18-0

Targets

Q8TDQ0HAVCR2

What you can answer from here — as of July 09, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

7Clinical trialsPhase, status and sponsor resolved per trial

4+ReferencesStructured and connected to the statements they support

Which drugs share a target with Verzistobart, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account